Aytu BioPharma (AYTU) 10-Q 6 Nov 15 2015 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2015	Nov. 01, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q1
Trading Symbol	AYTU
Entity Registrant Name	AYTU BIOSCIENCE, INC.
Entity Central Index Key	1,385,818
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		14,259,693

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2015	Jun. 30, 2015
Current assets
Cash and cash equivalents	$ 10,069,025	$ 7,353,061
Accounts receivable	167,930	157,058
Inventory	494,080	39,442
Prepaid expenses, other	360,531	370,888
Prepaid research and development - related party (Note 11)	121,983	121,983
Deferred tax asset	94,211	41,427
Total current assets	11,307,760	8,083,859
Fixed assets, net (Note 2)	26,374	29,706
Developed technology, net	760,375	780,125
Customer contracts, net	693,000	711,000
Trade names, net	77,000	79,000
Goodwill	74,000	74,000
In-process research and development	7,500,000	7,500,000
Patents, net	611,079	628,776
Long-term portion of prepaid research and development - related party (Note 11)	304,958	335,454
Deposits	4,886	4,886
Total non current assets	10,051,672	10,142,947
Total assets	21,359,432	18,226,806
Current liabilities
Accounts payable	1,075,133	1,196,817
Accrued compensation	617,041	196,503
Deferred revenue	85,714	85,714
Total current liabilities	1,777,888	1,479,034
Convertible promissory notes, net of amortization discount of $349,690 (Note 8)	4,825,310
Contingent consideration	677,153	664,000
Long-term deferred revenue	404,465	425,893
Interest payable	57,637
Deferred rent	11,379
Non-current deferred tax liability	94,211	41,427
Warrant derivative liability	102,803
Total liabilities	$ 7,950,846	$ 2,610,354
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued
Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 14,259,681 as of September 30, 2015 and June 30, 2015	$ 1,426	$ 1,426
Additional paid-in capital	39,064,689	38,996,367
Ampio stock subscription	(5,000,000)	(5,000,000)
Accumulated deficit	(20,657,529)	(18,381,341)
Total stockholders' equity	13,408,586	15,616,452
Total liabilities and stockholders' equity	$ 21,359,432	$ 18,226,806

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Jun. 30, 2015
Statement of Financial Position [Abstract]
Convertible promissory notes, amortization discount	$ 349,690
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized shares	50,000,000	50,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized shares	300,000,000	300,000,000
Common stock, issued shares	14,259,681	14,259,681
Common stock, outstanding shares	14,259,681	14,259,681

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Product and service revenue	$ 465,956	$ 6,154
License revenue	21,429	21,429
Total revenue	487,385	27,583
Expenses
Cost of sales	37,325	225
Research and development	855,874	933,753
Research and development - related party (Note 11)	47,998	53,998
Sales, general and administrative	1,709,251	1,131,276
Loss from operations	(2,163,063)	(2,091,669)
Other (expense) income
Interest and other (expense)	(113,125)	(37,302)
Total other (expense) income	(113,125)	(37,302)
Net loss, before income tax	(2,276,188)	(2,128,971)
Deferred income tax benefit	0	23,910
Net loss	$ (2,276,188)	$ (2,105,061)
Weighted average number of Aytu common shares outstanding	14,259,681	7,901,426
Basic and diluted Aytu net loss per common share	$ (0.16)	$ (0.27)

Statements of Stockholders' Equ

Statements of Stockholders' Equity - 3 months ended Sep. 30, 2015 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Receivables from Stockholder [Member]	Accumulated Deficit [Member]
Beginning Balance at Jun. 30, 2015	$ 15,616,452	$ 1,426	$ 38,996,367	$ (5,000,000)	$ (18,381,341)
Beginning Balance, shares at Jun. 30, 2015		14,259,681
Stock-based compensation (unaudited)	68,322		68,322
Stock-based compensation (unaudited), shares		0
Net loss (unaudited)	(2,276,188)				(2,276,188)
Ending Balance at Sep. 30, 2015	$ 13,408,586	$ 1,426	$ 39,064,689	$ (5,000,000)	$ (20,657,529)
Ending Balance, shares at Sep. 30, 2015		14,259,681

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net loss	$ (2,276,188)	$ (2,105,061)
Stock-based compensation expense	68,322	202,011
Depreciation, amortization and accretion	128,921	24,582
Amortization of prepaid research and development - related party (Note 11)	30,496	30,496
Deferred taxes	0	(23,909)
Adjustments to reconcile net loss to net cash used in operating activities:
(Increase) in accounts receivable	(10,872)
(Increase) in inventory	(454,638)
Decrease in prepaid expenses, other	10,357	515,107
(Increase) in prepaid research and development - related party (Note 11)	0	(150,000)
(Decrease) in accounts payable and accrued liabilities	0	(136,188)
Increase in interest payable to Ampio		37,375
Increase in accrued compensation	420,538
(Decrease) in payable to Ampio	0	(561,059)
Increase in interest payable	57,637
Increase in deferred rent	11,379
(Decrease) in deferred revenue	(21,428)	(21,429)
Net cash used in operating activities	(2,157,160)	(2,188,075)
Cash flows used in investing activities
Purchases of property and equipment	(3,554)
Net cash used in investing activities	(3,554)
Cash flows from financing activities
Proceeds from convertible promissory notes (Note 8)	5,175,000
Debt issuance costs (Note 8)	(298,322)
Contribution from Ampio	0	600,000
Net cash provided by financing activities	4,876,678	600,000
Net change in cash and cash equivalents	2,715,964	(1,588,075)
Cash and cash equivalents at beginning of period	7,353,061	2,639,650
Cash and cash equivalents at end of period	10,069,025	$ 1,051,575
Non-cash transactions:
Warrant derivative liability (Note 8)	$ 102,931

Business, Acquisition of Assets

Business, Acquisition of Assets and Basis of Presentation	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Business, Acquisition of Assets and Basis of Presentation	Note 1 – Business, Acquisition of Assets and Basis of Presentation Business/Acquisition of Assets Aytu BioScience, Inc. (“Aytu” or the “Company”) was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June 8, 2015. Aytu is a specialty healthcare company concentrating on developing and commercializing products focused primarily on the urological disorders market, specifically sexual dysfunction, urological cancer and male infertility. Basis of Presentation These unaudited financial statements represent the financial statements of Aytu BioScience, Inc. (“Aytu” or “the Company”). These unaudited financial statements should be read in conjunction with Aytu’s Annual Report on Form 10-K for the year ended June 30, 2015, which included all disclosures required by generally accepted accounting principles (“GAAP”). In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended September 30, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended September 30, 2015 is unaudited. Aytu’s current business was formed through a reverse triangular merger (the “Merger”) in which Luoxis Diagnostics, Inc. (“Luoxis”) and Vyrix Pharmaceuticals, Inc. (“Vyrix”) merged into Rosewind Corporation in a multi-step merger on April 16, 2015. These historical financial statements prior to April 16, 2015 include the combined financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the “Vyrix Acquired Assets”) from March 23, 2011, the date its parent company, Ampio Pharmaceuticals, Inc. (“Ampio”), originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (“BioSciences”) and the financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis. The carve-out financial statements present the statements of financial position of Vyrix and Luoxis and the Vyrix Acquired Assets and the statements of operations and cash flows for purposes of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, General Instructions to Financial Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements. Historically, financial statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entity. Although Vyrix and Luoxis have not been segregated as a separate legal entity, related revenues, direct costs and expenses, assets and liabilities have historically been segregated on Ampio’s books. In addition, the Company allocated corporate overhead costs based on a review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor and other overhead totaled $264,000 in 2015 and $253,000 in 2014. The Company also prepared a calculation of income tax expense and deferred income tax assets and liabilities on a “separate return” basis. These financial statements do not include a carve-out for cash as the operations have historically been funded by Ampio. The historical carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as a stand-alone entity. The “Company” as referred to in the notes to these financial statements includes Vyrix and Luoxis, collectively. As of September 30, 2015, Ampio is the majority shareholder of 81.5% of Aytu’s outstanding common stock. On June 8, 2015, in connection with the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received one share of common stock for each every 12.174 shares then outstanding (the “Reverse Stock Split”). All share and per share amounts in this Report have been adjusted to reflect the effect of the Reverse Stock Split. Business Combination – ProstaScint In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as ProstaScint ® The purchase price consisted of the upfront payment of $1.0 million. Aytu also agreed to pay an additional $500,000 payable within five days after transfer for the ProstaScint-related product inventory and $227,000 that was paid subsequent to September 30, 2015 (which represents a portion of certain FDA fees). Aytu also will pay 8% as contingent consideration on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was valued at $664,000 using a discounted cash flow estimate as of the acquisition date. The total fair value consideration for the purchase was $2.4 million. The Company’s allocation on consideration transferred for ProstaScint as of the purchase date of May 20, 2015 is as follows: Estimated Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000 Included in the intangible assets is Developed technology of $790,000, Customer contracts of $720,000 and Trade names of $80,000, each of which will be amortized over a ten-year period. As of September 30, 2015 the contingent consideration had increased to $677,000 due to accretion. Newly Issued Accounting Pronouncements In September 2015, the Financial Accounting Standards Board, (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of September 30, 2015, the Company early adopted this standard. In July 2015, the FASB issued ASU 2015-12, “Plan Accounting: Defined Benefits Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962) and Health and Welfare Benefit Plans (Topic 965): I. Fully Benefit-Responsive Investment Contracts; II. Plan Investment Disclosures; and III. Measurement Date Practical Expedient.” This three-part ASU simplifies current benefit plan accounting and requires (i) fully benefit-responsive investment contracts to be measured, presented, and disclosed only at contract value and accordingly removes the requirement to reconcile their contract value to fair value; (ii) benefit plans to disaggregate their investments measured using fair value by general type, either on the face of the financial statements or in the notes to the financial statements; (iii) the net appreciation or depreciation in investments for the period to be presented in the aggregate rather than by general type, and removes certain disclosure requirements relevant to individual investments that represent five percent or more of net assets available for benefits. Further, the amendments in this ASU eliminate the requirement to disclose the investment strategy for certain investments that are measured using Net Asset Value (“NAV”) per share using the practical expedient in the FASB ASC Topic 820. Part III of the ASU provides a practical expedient to permit employee benefit plans to measure investments and investment-related accounts as of the month-end that is closest to the plan’s fiscal year-end, when the fiscal period does not coincide with a month-end, while requiring certain additional disclosures. The amendments in Parts I and II of this standard are effective retrospectively for fiscal years beginning after December 15, 2015 and early adoption is permitted. The amendments in Part III of this standard are effective prospectively for fiscal years beginning after December 15, 2015 and early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company’s financial position or results of operations. In June 2015, the FASB issued ASU 2015-10, “Technical Corrections and Improvements”. The amendments represent changes to clarify the codification, correct unintended application of guidance, or make minor improvements to the codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost. In addition, some of the amendments will make the codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the codification. The amendments that require transition guidance are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. All other amendments will be effective upon issuance. The Company is evaluating the impact of ASU 2015-10 on its financial statements. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation In January 2015, the FASB issued ASU 2015-01, “Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. The Company is evaluating the impact the adoption of ASU 2015-01 will have on its financial statements. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. The Company is currently evaluating the effect that the updated standard will have on its financial statements.

Fixed Assets

Fixed Assets	3 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 2 – Fixed Assets Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following: Estimated As of September 30, As of June 30, Leasehold improvements 3 3,000 — Lab equipment 3 – 5 90,000 90,000 Less accumulated depreciation and amortization (67,000 ) (60,000 ) Fixed assets, net $ 26,000 $ 30,000

In-Process Research and Develop

In-Process Research and Development	3 Months Ended
	Sep. 30, 2015
Research and Development [Abstract]
In-Process Research and Development	Note 3 – In-Process Research and Development In-process research and development (“IPRD”) relates to the Zertane product candidate. The $7,500,000 recorded was based on an independent, third party appraisal of the fair value of the assets acquired. IPRD is considered an indefinite-lived intangible asset and its fair value will be assessed annually and written down if impaired. If the Zertane product candidate obtains regulatory approval and commercial production begins, IPRD will be reclassified to an intangible that will be amortized over its estimated useful life. If the Company decides to abandon the Zertane product, the IPRD would be expensed.

Patents

Patents	3 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 4 – Patents Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent, third party appraisal to be $500,000 is being amortized over the remaining U.S. patent lives of approximately 11 years. The cost of the ORP related patents was $380,000 when they were acquired and is being amortized over the remaining U.S. patent lives of approximately 15 years. Patents consist of the following: As of September 30, As of June 30, Patents $ 880,000 $ 880,000 Less accumulated armortization (269,000 ) (251,000 ) Patents, net $ 611,000 $ 629,000

Revenue Recognition

Revenue Recognition	3 Months Ended
	Sep. 30, 2015
Text Block [Abstract]
Revenue Recognition	Note 5 – Revenue Recognition The $466,000 and $6,000 product and service revenue recognized during the three months ended September 30, 2015 and 2014, respectively, represents sales of our ProstaScint product and the RedoxSYS System. The license revenue recognized in the three months ended 2015 and 2014, respectively, represents the amortization of the upfront payments received from our license agreements. The initial payment of $500,000 from the license agreement of Zertane with a Korean pharmaceutical company was deferred and is being recognized over ten years. The initial payment of $250,000 from the license agreement of Zertane with a Canadian-based supplier was deferred and is being recognized over seven years.

Fair Value Considerations

Fair Value Considerations	3 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Fair Value Considerations	Note 6 – Fair Value Considerations Aytu’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, convertible promissory notes and warrant derivative liability. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the convertible notes is approximately the face value of the notes, $5,175,000 based upon the valuation that the Company had completed of all components of the convertible notes at inception and as of September 30, 2015. The valuation policies are determined by the Chief Financial Officer and approved by the Company’s Board of Directors as deemed appropriate. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. Aytu’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented. The following table presents Aytu’s financial liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total September 30, 2015 LIABILITIES Warrant derivative liability $ — $ — $ 103,000 $ 103,000 The warrant derivative liability for the warrants was valued using the Monte Carlo valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions in valuing the warrant derivative liability based on estimates of the value of our common stock and various factors regarding the warrants, were as follows as of September 30, 2015 and at issuance: September 30, 2015 At Issuance Warrants: Exercise price $1.51 - $1.95 $1.51 - $1.95 Volatility 75.0 % 75.0 % Equivalent term (years) 4.92 5.0 - 5.11 Risk-free interest rate 1.35 % 1.54% - 1.74 % Potential number of shares 141,000 - 189,000 139,000 - 224,000 The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: Derivative Instruments Balance as of June 30, 2015 $ — Warrant issuances 102,931 Included in earnings (128 ) Balance as of September 30, 2015 $ 102,803

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table for the designated fiscal years ending June 30, as of September 30: Total Remaining 2017 2018 2019 2020 Thereafter Management fee 1,710,000 270,000 360,000 360,000 360,000 360,000 — Office Lease 419,000 102,000 142,000 145,000 30,000 — — Clinical research and trial obligations 266,000 266,000 — — — — — Sponsored research agreement with related party 333,000 53,000 70,000 70,000 70,000 70,000 — $ 2,728,000 $ 691,000 $ 572,000 $ 575,000 $ 460,000 $ 430,000 $ — Management Fee In July 2015, Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. These agreements will be in effect until they are terminated in writing by both parties. Office Lease In June 2015, Aytu entered into a 37 month operating lease for a space in Raleigh, North Carolina. This lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. In September 2015, the Company entered into a 37 month operating lease in Englewood, Colorado. This lease has an initial base rent of $8,500 a month with a total base rent over the term of the lease of approximately $318,000. The Company recognizes rental expense of the facilities on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows: Three Months Ended September 30, 2015 2014 Rent expense $ 18,000 $ 19,000 Clinical Research and Trial Obligations In connection with the Zertane clinical trials and RedoxSYS research studies, the remaining commitment is $266,000. Sponsored Research Agreement with Related Party Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days’ notice.

Convertible Promissory Notes

Convertible Promissory Notes	3 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Convertible Promissory Notes	Note 8 – Convertible Promissory Notes Convertible Promissory Notes During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes (“Notes”) with an aggregate principal amount of $5.2 million. The sale of the Notes was pursuant to a private placement. Debt issuance costs totaled $401,000 which includes $103,000 fair value of the warrants. The Notes are an unsecured obligation. Unless earlier converted, the Notes will mature 18 months from their respective dates of issuance which will be on January 22, February 11 and February 28, 2017, with an option to extend the maturity date up to six months at Aytu’s discretion (provided that in the event Aytu exercises such extension option, the then applicable interest rate shall increase by 2% for such extension period). Aytu does not have the right to prepay the Notes prior to the maturity date. Interest will accrue on the Notes in the following amounts: (i) 8% simple interest per annum for the first six months and (ii) 12% simple interest per annum thereafter if not converted during the first six months. If there has not been a registration statement on Form S-1 filed with the SEC for the registration of the shares of common stock underlying the Notes by the expiration of the first six-month period then (a) the interest rate will increase to 14% for the remainder of the period in which the Notes remain outstanding and (b) any Notes held by officers and directors of the Company will be subordinated to the remaining Notes. Interest will accrue, is payable with the principal upon maturity, conversion or acceleration of the Notes and may be paid in kind or in cash, in Aytu’s sole discretion. The 4% increase in the interest rate is triggered automatically with the passage of time and is not a contingent feature, thus, there is no initial accounting for this feature. However, the periodic interest cost will be calculated using a constant effective interest over the life of the Notes. As management does not intend to utilize the extension option, the expected life of the Notes is 18 months. The Company did not give recognition to the registration rights arrangement as management did not believe at issuance that probable payment under the contingent escalation clause would be required, thus there was no impact on the initial measurement of the Notes. The Company satisfied the registration rights arrangement in October 2015 upon the effectiveness of a registration statement on Form S-1. The Notes are convertible at any time at the noteholder’s discretion into that number of shares of Aytu common stock equal in an amount equal to 120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of Notes will be obligated to convert on the terms of Aytu’s next public offering of its stock resulting in gross proceeds of at least $5,000,000 (excluding indebtedness converted in such financing) prior to the maturity date of the Notes (a “Qualified Financing”). The principal and accrued interest under the Notes will automatically convert into a number of shares of such equity securities of the Company sold in the Qualified Financing equal to 120% of the principal and accrued interest under such Note divided by the lesser of (i) the lowest price paid by an investor in the Qualified Financing or (ii) $4.63. In the event that Aytu sells equity securities to investors at any time while the Notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (i) the lowest cash price per share paid by purchasers of shares in such financing, or (ii) $4.63. The Company determined that the conversion option is not required to be bifurcated and accounted for as an embedded derivative liability. There was no intrinsic value to the beneficial conversion feature as it was determined that the effective conversion price exceeded the commitment date valuation price. The Notes contained a purchase premium option in the event of a sale transaction as defined in the Notes. A holder of the Notes will be entitled to receive, at the holder’s option, (i) repayment of the Note balance plus the amount equal to 25% of the original purchase amount or (ii) the consideration the holder would have received on an as-converted basis. Given that the payment under the purchase premium is contingent upon a sale transaction and involves a substantial premium of 25%, the purchase premium is an embedded derivative that must be bifurcated and accounted for as an embedded derivative. No value was recorded related to this derivative at issuance and September 30, 2015. Newbridge Securities Corporation, a FINRA/SIPC member, through LifeTech Capital, acted as sole placement agent for the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom Aytu has an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent 8% of the gross proceeds of Notes sold by the placement agent and is obligated to issue warrants for an amount of shares to be equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents in the private placement, in addition to a previously paid non-refundable retainer fee of $20,000. The placement agent warrant has a term of five years, will have an exercise price equal to the lowest conversion price per share at which the Notes are converted into common stock. Change in fair value is recorded in earnings. Fair value at the grant date was recorded as a debt discount and amortized over the term of the debt. The warrants were recorded at fair value as long-term liabilities on the Balance Sheet. See Note 4. Per our adoption of ASU 2015-3, the costs associated with the Notes were recorded as a long–term liability and are presented in the Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date. As of September 30, 2015, the carrying value of the Notes was $4.8 million inclusive of an unamortized debt discount of $350,000.

Common Stock

Common Stock	3 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Common Stock	Note 9 – Common Stock Capital Stock At September 30, 2015 and June 30, 2015, Aytu had 300 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share.

Equity Instruments

Equity Instruments	3 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Instruments	Note 10 – Equity Instruments Options Prior to the Merger, Aytu had two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 1,718,828 million shares of common stock, both of which were terminated on April 16, 2015 upon the closing of the Merger. The Luoxis options that were in the money and all outstanding Vyrix options issued under the respective 2013 Option Plans were accelerated and cancelled in connection with the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the option; if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the period ended June 30, 2015 was $27,000. The Company recognized compensation of $422,000 and $189,000 related to the Luoxis and Vyrix options that had accelerated vesting as of the Merger date during the period ended June 30, 2015. The Luoxis options that were not paid out were terminated pursuant to the terms of the 2013 Luoxis Option Plan. The Company treated these options as pre-vesting forfeitures and $433,000 of previously recognized compensation was reversed. On June 1, 2015, Aytu’s stockholders approved the 2015 Stock Option and Incentive Plan (the “2015 Plan”), which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10,000,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan. The fair value of the options are calculated using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Aytu has computed the fair value of all options granted during the three months ended September 30, 2015 using the following assumptions: Expected volatility 75.00% Risk free interest rate 1.08% – 1.59% Expected term (years) 3.0 – 4.5 Dividend yield 0% Stock option activity is as follows: Number of Weighted Weighted Average Outstanding June 30, 2015 — $ — Granted 50,000 $ 4.63 Exercised — $ — Forfeited/Cancelled — $ — Outstanding September 30, 2015 50,000 $ 4.63 4.86 Exercisable at September 30, 2015 — $ — Available for grant at September 30, 2015 9,950,000 Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and selling, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation expense for the three months ended September 30, 2015 and for the stock-based compensation expense related to the Luoxis and Vyrix options for the three months ended September 30, 2014: Three Months Ended September 30, 2015 2014 Research and development expenses Stock options $ 5,000 $ 90,000 Selling, general and administrative expenses Stock options 63,000 112,000 $ 68,000 $ 202,000 Unrecognized expense at September 30, 2015 $ 10,000 Weighted average remaining years to vest 3.55 Warrants Aytu issued warrants in conjunction with its 2013 private placement. A summary of these warrants is as follows: Number of Weighted Weighted Average Outstanding June 30, 2015 102,613 $ 4.53 2.92 Outstanding September 30, 2015 (unaudited) 102,613 $ 4.53 2.92 Warrant Obligation related to the Convertible Promissory Notes Aytu has the obligation to issue warrants to the private placement agents as part of their fees for the convertible note financing. These warrants are classified as a derivative warrant liability due to the fact that the number of shares and exercise price have not been set as of September 30, 2015. The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The exercise price will be the lowest conversion price per share at which the Notes are converted into Company common stock. The warrants have a term of five years from August 31, 2015.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 – Related Party Transactions Ampio Loan Agreement In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $3,000,000 through cash advances of up to $500,000 each. Unpaid principal amounts under the loan agreement bear simple interest at the “Applicable Federal Rate” for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Vyrix may repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Vyrix common stock at the fair market value per share of Vyrix common stock, as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $1,600,000 with interest rates from 3.11%-3.32%. On April 16, 2015, in connection with the closing of the Merger, Ampio released Vyrix from its then outstanding obligation of $4,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $3,000,000. Unpaid principal amounts under the loan agreement bear simple interest at the “Applicable Federal Rate” for long-term obligations prescribed under Section 1274(d) of the Internal Revenue Code of 1986, as amended (or any successor provision with similar applicability). The initial term of this loan agreement is for one year, subject to automatic extension of successive one-year terms. Luoxis may repay any outstanding balance at any time without penalty. Ampio has an option of converting any balance outstanding under the loan agreement into shares of Luoxis common stock at the fair market value per share of Luoxis common stock, as determined by the Ampio board of directors, as of such conversion date. As of June 30, 2014, the amount advanced was $3,000,000 with interest rates from 3.11% – 3.32%. On April 16, 2015, in connection with the closing of the Merger, Ampio released Luoxis from its then outstanding obligation of $8,000,000 under the loan agreement as consideration of its share purchase, and the loan agreement was terminated. On April 16, 2015, Ampio received 4,761,787 shares of common stock of Aytu for (i) issuance to Aytu of a promissory note from Ampio in the principal amount of $10,000,000, maturing on the first anniversary of the Merger, (ii) cancellation of indebtedness of Luoxis to Ampio in the amount of $8,000,000; and (iii) cancellation of indebtedness of Vyrix to Ampio in the amount of $4,000,000. Services Agreement The Company has entered into a service agreement with Ampio which is described in Note 7. Sponsored Research Agreement In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio’s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related to research and development of the RedoxSYS platform. In March 2014, Luoxis also agreed to pay $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement is set to expire March 2019 and cannot be terminated prior to March 2017. Convertible Promissory Notes The convertible promissory notes (see Note 8) include $275,000 invested by relatives of senior management of the Company.

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 12 – Subsequent Events On October 5, 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as Primsol ® Aytu paid $500,000 at closing for the Primsol Business and also agreed to pay an additional $142,000 payable within five days after transfer of the Primsol-related product inventory. Aytu also agreed to pay an additional (a) $500,000 payable no later than March 31, 2016, (b) $500,000 payable no later than June 30, 2016, and (c) $250,000 payable no later than September 30, 2016 (together, the “Installment Payments”). On October 8, 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (“Biovest”). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products. The agreement provides customary terms and conditions, including those for performance of services by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at our expense, during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, Aytu may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason. In conjunction with entering into the agreement, Aytu submitted a work order to Biovest to provide Aytu with active pharmaceutical ingredient for ProstaScint over a four-year period at a total cost of $5,000,000, of which we paid $1,000,000 upon submission of the work order and anticipate paying the remaining balance as follows in fiscal: 2016 $ 1,500,000 2017 1,500,000 2018 500,000 2019 500,000 $ 4,000,000

Business, Acquisition of Asse19

Business, Acquisition of Assets and Basis of Presentation (Policies)	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Newly Issued Accounting Pronouncements	Newly Issued Accounting Pronouncements In September 2015, the Financial Accounting Standards Board, (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of September 30, 2015, the Company early adopted this standard. In July 2015, the FASB issued ASU 2015-12, “Plan Accounting: Defined Benefits Pension Plans (Topic 960), Defined Contribution Pension Plans (Topic 962) and Health and Welfare Benefit Plans (Topic 965): I. Fully Benefit-Responsive Investment Contracts; II. Plan Investment Disclosures; and III. Measurement Date Practical Expedient.” This three-part ASU simplifies current benefit plan accounting and requires (i) fully benefit-responsive investment contracts to be measured, presented, and disclosed only at contract value and accordingly removes the requirement to reconcile their contract value to fair value; (ii) benefit plans to disaggregate their investments measured using fair value by general type, either on the face of the financial statements or in the notes to the financial statements; (iii) the net appreciation or depreciation in investments for the period to be presented in the aggregate rather than by general type, and removes certain disclosure requirements relevant to individual investments that represent five percent or more of net assets available for benefits. Further, the amendments in this ASU eliminate the requirement to disclose the investment strategy for certain investments that are measured using Net Asset Value (“NAV”) per share using the practical expedient in the FASB ASC Topic 820. Part III of the ASU provides a practical expedient to permit employee benefit plans to measure investments and investment-related accounts as of the month-end that is closest to the plan’s fiscal year-end, when the fiscal period does not coincide with a month-end, while requiring certain additional disclosures. The amendments in Parts I and II of this standard are effective retrospectively for fiscal years beginning after December 15, 2015 and early adoption is permitted. The amendments in Part III of this standard are effective prospectively for fiscal years beginning after December 15, 2015 and early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company’s financial position or results of operations. In June 2015, the FASB issued ASU 2015-10, “Technical Corrections and Improvements”. The amendments represent changes to clarify the codification, correct unintended application of guidance, or make minor improvements to the codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost. In addition, some of the amendments will make the codification easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the codification. The amendments that require transition guidance are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. All other amendments will be effective upon issuance. The Company is evaluating the impact of ASU 2015-10 on its financial statements. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation In January 2015, the FASB issued ASU 2015-01, “Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. The Company is evaluating the impact the adoption of ASU 2015-01 will have on its financial statements. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. The Company is currently evaluating the effect that the updated standard will have on its financial statements.

Business, Acquisition of Asse20

Business, Acquisition of Assets and Basis of Presentation (Tables)	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Company's Allocation on Consideration Transferred for ProstaScint	The Company’s allocation on consideration transferred for ProstaScint as of the purchase date of May 20, 2015 is as follows: Estimated Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following: Estimated As of September 30, As of June 30, Leasehold improvements 3 3,000 — Lab equipment 3 – 5 90,000 90,000 Less accumulated depreciation and amortization (67,000 ) (60,000 ) Fixed assets, net $ 26,000 $ 30,000

Patents (Tables)

Patents (Tables)	3 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents	Patents consist of the following: As of September 30, As of June 30, Patents $ 880,000 $ 880,000 Less accumulated armortization (269,000 ) (251,000 ) Patents, net $ 611,000 $ 629,000

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	3 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Financial liabilities Accounted Fair Value on Recurring Basis	The following table presents Aytu’s financial liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total September 30, 2015 LIABILITIES Warrant derivative liability $ — $ — $ 103,000 $ 103,000
Significant Assumptions in Valuing Warrant Derivative Liability	Significant assumptions in valuing the warrant derivative liability based on estimates of the value of our common stock and various factors regarding the warrants, were as follows as of September 30, 2015 and at issuance: September 30, 2015 At Issuance Warrants: Exercise price $1.51 - $1.95 $1.51 - $1.95 Volatility 75.0 % 75.0 % Equivalent term (years) 4.92 5.0 - 5.11 Risk-free interest rate 1.35 % 1.54% - 1.74 % Potential number of shares 141,000 - 189,000 139,000 - 224,000
Reconciliation of Changes in Fair Value of Financial Liabilities Classified As Level 3	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: Derivative Instruments Balance as of June 30, 2015 $ — Warrant issuances 102,931 Included in earnings (128 ) Balance as of September 30, 2015 $ 102,803

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Summary of Commitments and Contingencies	Commitments and contingencies are described below and summarized by the following table for the designated fiscal years ending June 30, as of September 30: Total Remaining 2017 2018 2019 2020 Thereafter Management fee 1,710,000 270,000 360,000 360,000 360,000 360,000 — Office Lease 419,000 102,000 142,000 145,000 30,000 — — Clinical research and trial obligations 266,000 266,000 — — — — — Sponsored research agreement with related party 333,000 53,000 70,000 70,000 70,000 70,000 — $ 2,728,000 $ 691,000 $ 572,000 $ 575,000 $ 460,000 $ 430,000 $ —
Rent Expense	Rent expense for the respective periods is as follows: Three Months Ended September 30, 2015 2014 Rent expense $ 18,000 $ 19,000

Equity Instruments (Tables)

Equity Instruments (Tables)	3 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options Valuation Assumption	time of the grant for treasury securities of similar maturity. Aytu has computed the fair value of all options granted during the three months ended September 30, 2015 using the following assumptions: Expected volatility 75.00% Risk free interest rate 1.08% – 1.59% Expected term (years) 3.0 – 4.5 Dividend yield 0%
Stock Option Activity	Stock option activity is as follows: Number of Weighted Weighted Average Outstanding June 30, 2015 — $ — Granted 50,000 $ 4.63 Exercised — $ — Forfeited/Cancelled — $ — Outstanding September 30, 2015 50,000 $ 4.63 4.86 Exercisable at September 30, 2015 — $ — Available for grant at September 30, 2015 9,950,000
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense for the three months ended September 30, 2015 and for the stock-based compensation expense related to the Luoxis and Vyrix options for the three months ended September 30, 2014: Three Months Ended September 30, 2015 2014 Research and development expenses Stock options $ 5,000 $ 90,000 Selling, general and administrative expenses Stock options 63,000 112,000 $ 68,000 $ 202,000 Unrecognized expense at September 30, 2015 $ 10,000 Weighted average remaining years to vest 3.55
Warrants Issued in Conjunction with its Senior Convertible Debentures	A summary of these warrants is as follows: Number of Weighted Weighted Average Outstanding June 30, 2015 102,613 $ 4.53 2.92 Outstanding September 30, 2015 (unaudited) 102,613 $ 4.53 2.92

Business, Acquisition of Asse26

Business, Acquisition of Assets and Basis of Presentation - Additional Information (Detail)	Sep. 30, 2015USD ($)	Jun. 08, 2015	May. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2015USD ($)	May. 20, 2015USD ($)
Business Acquisition [Line Items]
Labor and other overhead costs				$ 264,000	$ 253,000
Percent of common stock				81.50%
Reverse stock split, description				On June 8, 2015, in connection with the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received one share of common stock for each every 12.174 shares then outstanding (the "Reverse Stock Split").
Reverse stock split ratio		12.174
Total fair value consideration							$ 2,391,000
Contingent consideration	$ 677,153			$ 677,153		$ 664,000
ProstaScint Business [Member]
Business Acquisition [Line Items]
Business Acquisition, acquisition cost			$ 1,000,000
Business Acquisition, liabilities incurred			500,000
Restructuring payment, contingent consideration				Aytu also will pay 8% as contingent consideration on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million.
Business Acquisition, future contingent payments			$ 2,500,000
Contingent consideration percentage			8.00%
Value of contingent consideration			$ 664,000
Total fair value consideration			$ 2,400,000
ProstaScint Business [Member] | Scenario, Forecast [Member]
Business Acquisition [Line Items]
Business Acquisition, liabilities incurred	227,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Maximum [Member]
Business Acquisition [Line Items]
Intangible assets amortized period				10 years
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Intangible assets gross	790,000			$ 790,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets gross	80,000			80,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Customer Contracts [Member]
Business Acquisition [Line Items]
Intangible assets gross	$ 720,000			$ 720,000

Business, Acquisition of Asse27

Business, Acquisition of Assets and Basis of Presentation - Company's Allocation on Consideration Transferred for ProstaScint (Detail) - USD ($)	Sep. 30, 2015	Jun. 30, 2015	May. 31, 2015	May. 20, 2015
Business Acquisition [Line Items]
Goodwill	$ 74,000	$ 74,000
Total assets acquired				$ 2,391,000
ProstaScint Business [Member]
Business Acquisition [Line Items]
Tangible assets				727,000
Intangible assets				1,590,000
Goodwill				$ 74,000
Total assets acquired			$ 2,400,000

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and amortization	$ (67,000)	$ (60,000)
Fixed assets, net	$ 26,374	29,706
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Fixed assets, gross	$ 3,000
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 90,000	$ 90,000
Lab Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Lab Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years

In-Process Research and Devel29

In-Process Research and Development - Additional Information (Detail)	Sep. 30, 2015USD ($)
Zertane Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
In-process research and development	$ 7,500,000

Patents - Additional Informatio

Patents - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2015USD ($)
Zertane Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Costs of establishing patents	$ 500,000
Remaining amortization period	11 years
ORP [Member]
Finite-Lived Intangible Assets [Line Items]
Costs of establishing patents	$ 380,000
Remaining amortization period	15 years

Patents - Schedule of Patents (

Patents - Schedule of Patents (Detail) - USD ($)	Sep. 30, 2015	Jun. 30, 2015
Indefinite-lived Intangible Assets [Line Items]
Patents, net	$ 611,079	$ 628,776
Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
Patents	880,000	880,000
Less accumulated amortization	(269,000)	(251,000)
Patents, net	$ 611,000	$ 629,000

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Revenue Recognition [Line Items]
Product and service revenue	$ 466,000	$ 6,000
KOREA | Korean Pharmaceutical Company [Member]
Revenue Recognition [Line Items]
Upfront payment received	$ 500,000	$ 500,000
Deferred revenue recognition period	10 years	10 years
CANADA | Canadian-based Supplier [Member]
Revenue Recognition [Line Items]
Upfront payment received	$ 250,000	$ 250,000
Deferred revenue recognition period	7 years	7 years

Fair Value Considerations - Add

Fair Value Considerations - Addition Information (Detail) - USD ($)	Sep. 30, 2015	Aug. 31, 2015
Debt Instrument Fair Value Carrying Value [Abstract]
Aggregate Principal Amount	$ 5,175,000	$ 5,175,000

Fair Value Considerations - Ayt

Fair Value Considerations - Aytu's Financial Liabilities Accounted for Fair Value Recurring Base (Detail) - USD ($)	Sep. 30, 2015	Aug. 31, 2015
LIABILITIES
Warrant derivative liability	$ 102,803	$ 102,803
Fair Value, Inputs, Level 1 [Member]
LIABILITIES
Warrant derivative liability	0
Fair Value, Inputs, Level 2 [Member]
LIABILITIES
Warrant derivative liability	0
Fair Value, Inputs, Level 3 [Member]
LIABILITIES
Warrant derivative liability	$ 102,803

Fair Value Considerations - Sig

Fair Value Considerations - Significant Assumption in Valuing Warrant Derivative Liability (Detail)	3 Months Ended
	Sep. 30, 2015$ / sharesshares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Equivalent term (years)	5 years
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	75.00%
Equivalent term (years)	4 years 11 months 1 day
Risk-free interest rate	1.35%
Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 1.51
Potential number of shares | shares	141,000
Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 1.95
Potential number of shares | shares	189,000
Issuance Date [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	75.00%
Issuance Date [Member] | Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 1.51
Equivalent term (years)	5 years
Risk-free interest rate	1.54%
Potential number of shares | shares	139,000
Issuance Date [Member] | Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 1.95
Equivalent term (years)	5 years 1 month 10 days
Risk-free interest rate	1.74%
Potential number of shares | shares	224,000

Fair Value Considerations - Rec

Fair Value Considerations - Reconciliation (Detail) - Fair Value, Inputs, Level 3 [Member]	3 Months Ended
	Sep. 30, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant issuances	$ 102,931
Included in earnings	(128)
Balance as of September 30, 2015	$ 102,803

Commitments and Contingencies -

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)	Sep. 30, 2015USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	$ 2,728,000
2,016	691,000
2,017	572,000
2,018	575,000
2,019	460,000
2,020	430,000
Thereafter	0
Management Fee [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	1,710,000
2,016	270,000
2,017	360,000
2,018	360,000
2,019	360,000
2,020	360,000
Thereafter	0
Office Lease [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	419,000
2,016	102,000
2,017	142,000
2,018	145,000
2,019	30,000
2,020	0
Thereafter	0
Clinical Research and Trial Obligations [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	266,000
2,016	266,000
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	0
Sponsored Research Agreement with Related Party [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	333,000
2,016	53,000
2,017	70,000
2,018	70,000
2,019	70,000
2,020	70,000
Thereafter	$ 0

Commitments and Contingencies38

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended
	Sep. 30, 2015	Jul. 31, 2015	Jun. 30, 2015	Sep. 30, 2015
Unrecorded Unconditional Purchase Obligation [Line Items]
Management fee payable to Ampio per month		$ 30,000
Remaining commitment for 2015	$ 2,728,000			$ 2,728,000
COLORADO
Unrecorded Unconditional Purchase Obligation [Line Items]
Operating lease period	37 months
Lease initial base rent per month	$ 8,500			8,500
Total base rent over the term of the lease	318,000
NORTH CAROLINA
Unrecorded Unconditional Purchase Obligation [Line Items]
Operating lease period			37 months
Lease initial base rent per month			$ 2,900
Total base rent over the term of the lease			$ 112,000
Sponsored Research Agreement with Related Party [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Remaining commitment for 2015	333,000			$ 333,000
Sponsored Research Agreement termination notice period				30 days
Clinical Research and Trial Obligations [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Remaining commitment for 2015	266,000			$ 266,000
Zertane Clinical Trials and RedoxSYS Research Studies [Member] | Clinical Research and Trial Obligations [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Remaining commitment for 2015	$ 266,000			$ 266,000

Commitments and Contingencies39

Commitments and Contingencies - Rent Expense (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 18,000	$ 19,000

Convertaible Promisssory Notes

Convertaible Promisssory Notes - Additional Information (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2015	Aug. 31, 2015
Debt Conversion [Line Items]
Purchase and sale of convertible promissory notes	$ 5,175,000	$ 5,175,000
Debt Issuance Cost	350,000	401,000
Warrant derivative liability	102,803	$ 102,803
Proceeds from convertible debt	5,175,000
Issuance Cost	$ 20,000
Percentage of amount paid to placement agent	8.00%
Warrant term	5 years
Convertible promissory notes, net (Note 6)	$ 4,825,310
Convertible Promissory Notes [Member]
Debt Conversion [Line Items]
Notes Maturity Period	18 months
Debt instrument interest rate for extension period	2.00%
Debt instrument interest rate for first six months	8.00%
Debt instrument interest rate thereafter	12.00%
Debt instrument interest rate	14.00%
Non contingent increase in interest rate that triggered automatically with passage of time	4.00%
Terms of Conversion Feature	The Notes are convertible at any time at the noteholder’s discretion into that number of shares of Aytu common stock equal in an amount equal to 120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of Notes will be obligated to convert on the terms of Aytu’s next public offering of its stock resulting in gross proceeds of at least $5,000,000 (excluding indebtedness converted in such financing) prior to the maturity date of the Notes (a “Qualified Financing”). The principal and accrued interest under the Notes will automatically convert into a number of shares of such equity securities of Aytu sold in the Qualified Financing equal to 120% of the principal and accrued interest under such Note divided by the lesser of (i) the lowest price paid by an investor in the Qualified Financing or (ii) $4.63. In the event that Aytu sells equity securities to investors at any time while the Notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (i) the lowest cash price per share paid by purchasers of shares in such financing, or (ii) $4.63.
Convertible notes equal to percentage of common stock	120.00%
Outstanding principal and accrued interest	$ 4.63
Notes Purchase premium option percentage	25.00%
Issuance Cost	$ 0
Convertible Promissory Notes [Member] | Minimum [Member]
Debt Conversion [Line Items]
Proceeds from convertible debt	$ 5,000,000
Convertible Promissory Notes [Member] | Convertible Promissory Notes One [Member]
Debt Conversion [Line Items]
Convertible promissory notes maturity date	Jan. 22, 2017
Convertible Promissory Notes [Member] | Convertible Promissory Notes Two [Member]
Debt Conversion [Line Items]
Convertible promissory notes maturity date	Feb. 11, 2017
Convertible Promissory Notes [Member] | Convertible Promissory Notes Three [Member]
Debt Conversion [Line Items]
Convertible promissory notes maturity date	Feb. 28, 2017

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - $ / shares	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014
Equity [Abstract]
Common stock, authorized shares	300,000,000	300,000,000	300,000,000
Common Stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, authorized shares	50,000,000	50,000,000	50,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001

Equity Instruments - Additional

Equity Instruments - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Sep. 30, 2015USD ($)Stock_Planshares	Sep. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 01, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option plan | Stock_Plan	2
Shares of common stock reserved for issuance | shares	1,718,828,000,000
Stock-based compensation expenses	$ 68,000	$ 202,000
Discription of warrant conversion	The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The exercise price will be the lowest conversion price per share at which the Notes are converted into Company common stock. The warrants have a term of five years from August 31, 2015.
Warrants term	5 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses			$ 27,000
Luoxis 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense			422,000
Reversal of share based compensation expense	$ 433,000
2015 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized for issuance | shares				10,000,000
Vyrix 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense			$ 189,000

Equity Instruments - Significan

Equity Instruments - Significant Assumptions (Detail) - Luoxis Diagnostics [Member]	3 Months Ended
	Sep. 30, 2015
Assumptions Used To Determine Fair Value Options [Line Items]
Expected volatility	75.00%
Risk free interest rate, minimum	1.08%
Risk free interest rate, maximum	1.59%
Dividend yield	0.00%
Minimum [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected term (years)	3 years
Maximum [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected term (years)	4 years 6 months

Equity Instruments - Luoxis Sto

Equity Instruments - Luoxis Stock Option Activity (Detail) - Luoxis Diagnostics [Member]	3 Months Ended
	Sep. 30, 2015$ / sharesshares
Number of Options
Number of Options, Granted	50,000
Number of Options, Exercised	0
Number of Options, Forfeited/Cancelled	0
Number of Options, Ending Balance	50,000
Number of Options, Exercisable	0
Number of Options, Available for grant	9,950,000
Weighted Average Exercise Price
Weighted Average Exercise Price, Granted | $ / shares	$ 4.63
Weighted Average Exercise Price, Exercised | $ / shares	0
Weighted Average Exercise Price, Forfeited/Cancelled | $ / shares	0
Weighted Average Exercise Price, Ending Balance | $ / shares	4.63
Weighted average exercise price, Exercisable | $ / shares	$ 0
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding	4 years 10 months 10 days

Equity Instruments - Summary of

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 68,000	$ 202,000
Unrecognized expense at September 30, 2015	$ 10,000
Weighted average remaining years to vest	3 years 6 months 18 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses			$ 27,000
Research and Development Expense [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 5,000	90,000
General and Administrative Expense [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 63,000	$ 112,000

Equity Instruments - Warrants I

Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	102,613
Number of Warrants Outstanding, Ending Balance	102,613	102,613
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 4.53
Weighted Average Exercise Price, Outstanding Ending Balance	$ 4.53	$ 4.53
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	2 years 11 months 1 day	2 years 11 months 1 day

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Apr. 16, 2015	Mar. 31, 2014	Nov. 30, 2013	Jun. 30, 2013	Sep. 30, 2015	Jun. 30, 2014	Aug. 31, 2015	Jun. 30, 2015
Related Party Transaction [Line Items]
Debt instrument principal amount					$ 5,175,000		$ 5,175,000
Shares of common stock					14,259,681			14,259,681
Ampio [Member]
Related Party Transaction [Line Items]
Shares of common stock	4,761,787
Ampio [Member] | Senior Management [Member]
Related Party Transaction [Line Items]
Convertible promissory notes					$ 275,000
Ampio [Member] | Scenario, Plan [Member] | Second Installment [Member]
Related Party Transaction [Line Items]
Equipment lease payments net				$ 615,000
Ampio [Member] | Scenario, Plan [Member] | Second Installment [Member] | After Amendment [Member]
Related Party Transaction [Line Items]
Monthly equipment lease payments				$ 6,000
Ampio [Member] | Scenario, Plan [Member] | First Installment [Member]
Related Party Transaction [Line Items]
Contract term					60 months 15 days
Lease expiration date					March 2,019
Ampio [Member] | Ampio Loan Agreement [Member]
Related Party Transaction [Line Items]
Total amount agreed on loan agreement		$ 3,000,000	$ 3,000,000
Term of loan agreement		1 year	1 year
Amount advances on loan agreement			$ 500,000
Ampio [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Debt instrument principal amount	$ 10,000,000
Ampio [Member] | Vyrix Pharmaceuticals [Member] | Ampio Loan Agreement [Member]
Related Party Transaction [Line Items]
Line of credit, remaining amount outstanding	4,000,000					$ 1,600,000
Loan agreement interest rate minimum						3.11%
Loan agreement interest rate maximum						3.32%
Ampio [Member] | Vyrix Pharmaceuticals [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Cancellation of indebtedness amount	4,000,000
Ampio [Member] | Luoxis Diagnostics [Member] | Ampio Loan Agreement [Member]
Related Party Transaction [Line Items]
Line of credit, remaining amount outstanding	8,000,000					$ 3,000,000
Loan agreement interest rate minimum						3.11%
Loan agreement interest rate maximum						3.32%
Ampio [Member] | Luoxis Diagnostics [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Cancellation of indebtedness amount	$ 8,000,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Oct. 08, 2015	Oct. 05, 2015
Scenario, Forecast [Member] | Primsol Business [Member]
Subsequent Event [Line Items]
Additional cash payable in business acquisition	$ 250,000	$ 500,000	$ 500,000
Subsequent Event [Member] | Biovest International, Inc. ("Biovest") [Member]
Subsequent Event [Line Items]
Master services agreement, term				4 years
Master services agreement, notice period for termination related to material breach				30 days
Master services agreement, notice period for termination				180 days
Master services agreement, aggregate consideration				$ 5,000,000
Master services agreement, amount paid				$ 1,000,000
Subsequent Event [Member] | Primsol Business [Member]
Subsequent Event [Line Items]
Cash paid to acquire business					$ 500,000
Additional cash payable in business acquisition					$ 142,000

Subsequent Events - Schedule of

Subsequent Events - Schedule of Purchase Obligation in Future Period (Detail) - Biovest International, Inc. ("Biovest") [Member] - Subsequent Event [Member]	Oct. 08, 2015USD ($)
Subsequent Event [Line Items]
2,016	$ 1,500,000
2,017	1,500,000
2,018	500,000
2,019	500,000
Total	$ 4,000,000